CoChat

HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration

Open access

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Immune attacks are key issues for cell transplantation. To assess the safety and the immune reactions after iPS cells-derived retinal pigment epithelium (iPS-RPE) transplantation, we transplanted HLA homozygote iPS-RPE cells established at an iPS bank in HLA-matched patients with exudative age-related macular degeneration. In addition, local steroids without immunosuppressive medications were administered. We monitored immune rejections by routine ocular examinations as well as by lymphocytes-graft cells immune reaction (LGIR) tests using graft RPE and the patient’s blood cells. In all five of the cases that underwent iPS-RPE transplantation, the presence of graft cells was indicated by clumps or an area of increased pigmentation at 6 months, which became stable with no further abnormal growth in the graft during the 1-year observation period. Adverse events observed included corneal erosion, epiretinal membrane, retinal edema due to epiretinal membrane, elevated intraocular pressure, endophthalmitis, and mild immune rejection in the eye. In the one case exhibiting positive LGIR tests along with a slight fluid recurrence, we administrated local steroid therapy that subsequently resolved the suspected immune attacks. Although the cell delivery strategy must be further optimized, the present results suggest that it is possible to achieve stable survival and safety of iPS-RPE cell transplantation for a year.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm9072217

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Beta values of the genomic blocks representing transcription start sites of cancer related genes. The beta values of RPE cells differentiated from iPS cells (QHJI01s04 iPS-RPE cells, n = 2) are comparable to those calculated for the eyes and control RPE cells (human primary RPE cells: Lonza RPE). The regions of the min-max beta values of the normal cells are shown in the gray color.
Figure 1 Beta values of the genomic blocks representing transcription start sites of cancer related genes. The beta values of RPE cells differentiated from iPS cells (QHJI01s04 iPS-RPE cells, n = 2) are comparable to those calculated for the eyes and control RPE cells (human primary RPE cells: Lonza RPE). The regions of the min-max beta values of the normal cells are shown in the gray color.CC BY · PubMed Central
Figure 2 Morphology, quality control tests, and expression of HLA molecules in established RPE cells from HLA homozygous iPS cells, and a candidate wet AMD patient, and procedures of the RPE cells transplantation. This study determined the morphology (A), phagocytosis of shed photoreceptor rod outer segments (ROS) (B), expression of RPE-specific markers (C), and production of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in the culture supernatants (D) from the iPS-RPE cells. (A) In our established RPE cells (QHJI01s04 iPS-RPE cells) we identified the hexagonal morphology that contained the pigment. (B) These RPE cells have phagocytic function (1. 37 °C incubation, 8 hr; 2. 4 °C incubation (control), 8 hr). (C) These RPE cells clearly expressed RPE-specific markers such as BEST1 (bestrophin-1), RPE65 (retinal pigment epithelium-specific 65 kDa protein), MERTK (Mer tyrosine kinase), and CRALBP (cellular retinaldehyde binding protein). GAPDH was the internal control in the cells. 1. QHJI01s04 iPS-RPE cells, line No. 1, QHJI01s04 iPS-RPE cells, line No. 2, 3. Water (negative control in PCR), 4. Human RPE cells (positive control in PCR). (D) The culture supernatants from QHJI01s04 iPS-RPE cells contained PEDF and VEGF: PEDF-apical (n = 3, Day-13), 336.95 ± 48.85 ng/mL, PEDF-basal (n = 3, Day-13), 99.25 ± 3.45 ng/mL, VEGF-apical (n = 3, Day-13), 1400 ± 0 pg/mL, VEGF-basal (n = 3, Day-13), 750 ± 50 pg/mL. We obtained similar data for the Day-20 supernatants. (E) In the present study, we used iPS-RPE cells (line QHJI01s04) from the HLA homozygous donor, HLA gene loci: A*24:02, B*52:01, C*12:02, DRB1*15:02, DQB1*06:01, and DPB1*09:01. (F) Expression of HLA-class I (A, B, C) and class II (DR, DQ, DP) on iPS-RPE cells. Right panels indicate IFN-γ pre-treatment. MFI—mean fluorescence intensity. We also determined the transplantation strategy for a candidate wet AMD patient (recipient: G) and the procedures for the transplantation (H). We transplanted RPE cell suspension (single cells: no sheet) into the subretinal space of the patients at this time.
Figure 2 Morphology, quality control tests, and expression of HLA molecules in established RPE cells from HLA homozygous iPS cells, and a candidate wet AMD patient, and procedures of the RPE cells transplantation. This study determined the morphology (A), phagocytosis of shed photoreceptor rod outer segments (ROS) (B), expression of RPE-specific markers (C), and production of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in the culture supernatants (D) from the iPS-RPE cells. (A) In our established RPE cells (QHJI01s04 iPS-RPE cells) we identified the hexagonal morphology that contained the pigment. (B) These RPE cells have phagocytic function (1. 37 °C incubation, 8 hr; 2. 4 °C incubation (control), 8 hr). (C) These RPE cells clearly expressed RPE-specific markers such as BEST1 (bestrophin-1), RPE65 (retinal pigment epithelium-specific 65 kDa protein), MERTK (Mer tyrosine kinase), and CRALBP (cellular retinaldehyde binding protein). GAPDH was the internal control in the cells. 1. QHJI01s04 iPS-RPE cells, line No. 1, QHJI01s04 iPS-RPE cells, line No. 2, 3. Water (negative control in PCR), 4. Human RPE cells (positive control in PCR). (D) The culture supernatants from QHJI01s04 iPS-RPE cells contained PEDF and VEGF: PEDF-apical (n = 3, Day-13), 336.95 ± 48.85 ng/mL, PEDF-basal (n = 3, Day-13), 99.25 ± 3.45 ng/mL, VEGF-apical (n = 3, Day-13), 1400 ± 0 pg/mL, VEGF-basal (n = 3, Day-13), 750 ± 50 pg/mL. We obtained similar data for the Day-20 supernatants. (E) In the present study, we used iPS-RPE cells (line QHJI01s04) from the HLA homozygous donor, HLA gene loci: A*24:02, B*52:01, C*12:02, DRB1*15:02, DQB1*06:01, and DPB1*09:01. (F) Expression of HLA-class I (A, B, C) and class II (DR, DQ, DP) on iPS-RPE cells. Right panels indicate IFN-γ pre-treatment. MFI—mean fluorescence intensity. We also determined the transplantation strategy for a candidate wet AMD patient (recipient: G) and the procedures for the transplantation (H). We transplanted RPE cell suspension (single cells: no sheet) into the subretinal space of the patients at this time.CC BY · PubMed Central
Figure 3 Color fundus, auto-fluorescence (AF), and indocyanine green angiography (IA) images before and at 1 year after the iPS cells-derived RPE cell transplantation in two cases. Representative fundus images during the 1-year follow-up are shown for Case 1 (A) and Case 2 (D). After surgery, grafted RPE cells were seen in the subretinal space around 3 and 8 weeks, respectively. Pigmented cells became visible by 6 months after the transplantation with a stable pigmented area observed at 1 year in both cases (white arrows). AF images (B,E) show a dark area that corresponds to the grafted cells at 1 year after the transplantation (white arrows). In IA images of Case 1 (C), yellow arrows indicate the presence of polyp lesions before the treatment. After 1 year, Case 1 developed a new polyp that was associated with hemorrhagic lesions on the lower margins of the PCV network (red arrows). On the other hand, there were no changes in the findings of the IA examination in Case 2 as compared with the pretreatment (F).
Figure 3 Color fundus, auto-fluorescence (AF), and indocyanine green angiography (IA) images before and at 1 year after the iPS cells-derived RPE cell transplantation in two cases. Representative fundus images during the 1-year follow-up are shown for Case 1 (A) and Case 2 (D). After surgery, grafted RPE cells were seen in the subretinal space around 3 and 8 weeks, respectively. Pigmented cells became visible by 6 months after the transplantation with a stable pigmented area observed at 1 year in both cases (white arrows). AF images (B,E) show a dark area that corresponds to the grafted cells at 1 year after the transplantation (white arrows). In IA images of Case 1 (C), yellow arrows indicate the presence of polyp lesions before the treatment. After 1 year, Case 1 developed a new polyp that was associated with hemorrhagic lesions on the lower margins of the PCV network (red arrows). On the other hand, there were no changes in the findings of the IA examination in Case 2 as compared with the pretreatment (F).CC BY · PubMed Central
Figure 4 Quantitative assessment of transplanted iPS-RPE cells in Case 2. Color fundus photographs and early phase fluorescein angiography (FAG) images obtained at pretreatment (A) and at 1 year after treatment (B). (C) Window defect (WD) shown by binary image processing of the FAG images at pretreatment. The FAG image was processed by binary imaging (C; left panel) and, then the vessel images was removed manually (C; right panel). Overlays of WD binary image for the pretreatment FA (D), and the FA at 1 year after treatment (E). WD area is displayed in pixels. (F) PS-OCT evaluation showed that the presence of pigmented RPE cells indicated the high-entropy area was above the RPE basement membrane and that there was a time-dependent decrease in the low-entropy area seen within the fovea-centered 3-mm-diameter circle. Low-entropy area at 1, 7, and 12 months after transplantation is shown in black on the entropy map for each time point with the percentage of black area within red circle. (G) Low-entropy areas for each of the time points were aligned with the retinal vessels and are shown on the right panel to demonstrate the consistency in the pattern. (H) Time course of a representative section view at the white line on the left color fundus image, which shows the continuity of the presumably melanin-containing RPE cells covering the surface of the fibrous tissue at 12 months after transplantation.
Figure 4 Quantitative assessment of transplanted iPS-RPE cells in Case 2. Color fundus photographs and early phase fluorescein angiography (FAG) images obtained at pretreatment (A) and at 1 year after treatment (B). (C) Window defect (WD) shown by binary image processing of the FAG images at pretreatment. The FAG image was processed by binary imaging (C; left panel) and, then the vessel images was removed manually (C; right panel). Overlays of WD binary image for the pretreatment FA (D), and the FA at 1 year after treatment (E). WD area is displayed in pixels. (F) PS-OCT evaluation showed that the presence of pigmented RPE cells indicated the high-entropy area was above the RPE basement membrane and that there was a time-dependent decrease in the low-entropy area seen within the fovea-centered 3-mm-diameter circle. Low-entropy area at 1, 7, and 12 months after transplantation is shown in black on the entropy map for each time point with the percentage of black area within red circle. (G) Low-entropy areas for each of the time points were aligned with the retinal vessels and are shown on the right panel to demonstrate the consistency in the pattern. (H) Time course of a representative section view at the white line on the left color fundus image, which shows the continuity of the presumably melanin-containing RPE cells covering the surface of the fibrous tissue at 12 months after transplantation.CC BY · PubMed Central
Figure 5 Findings of immune attacks in the eye of a transplanted AMD patient (Case 1). (A) FACS results in the lymphocytes-graft cells immune reaction (LGIR) test at 4 weeks after surgery in the AMD patient. For the LGIR test, there was a great proliferation of the CD4+/Ki-67+ (proliferative helper T cells) and CD11b+/Ki-67+ (proliferative monocytes) in PBMC as compared with the PBMC only (no RPE). (B) Color fundus photographs at 5 weeks after surgery of the transplanted AMD patient (Case 1), and (C) the autofluorescence (AF) fundus photographs (arrows, grafted RPE cells). (D) OCT image, grafted area (yellow bar) at 5 weeks. There were small amounts of subretinal fluids in the subretinal space (yellow arrow). The LGIR test at 8 weeks (E), showed that there was poor proliferation of the CD4+ T cells in PBMC that were exposed to transplanted iPS-RPE cells. On the other hand, the proliferation of the CD11b+ cells against RPE cells still remained. (F) Color fundus and AF photographs (G) at 8 weeks after surgery in the same patient. (H) OCT shows that the subretinal fluids disappeared after local steroid treatment. (I) Panels show fluorescence angiography images before and at 4 weeks after transplantation, (arrow, grafted RPE cells). There were no leakages from the grafted cells observed in the fluorescence angiography. (J) LGIR FACS results after surgery of the AMD patient (Case 1). There was a decrease in the CD4+/Ki-67+ double-positive cells observed after the sub-Tenon conjunctival injection (STTA; orange arrows), and a decreased in the CD11+/Ki-67+ double-positive cells at 36 weeks after administration of STTA for a total of three times.
Figure 5 Findings of immune attacks in the eye of a transplanted AMD patient (Case 1). (A) FACS results in the lymphocytes-graft cells immune reaction (LGIR) test at 4 weeks after surgery in the AMD patient. For the LGIR test, there was a great proliferation of the CD4+/Ki-67+ (proliferative helper T cells) and CD11b+/Ki-67+ (proliferative monocytes) in PBMC as compared with the PBMC only (no RPE). (B) Color fundus photographs at 5 weeks after surgery of the transplanted AMD patient (Case 1), and (C) the autofluorescence (AF) fundus photographs (arrows, grafted RPE cells). (D) OCT image, grafted area (yellow bar) at 5 weeks. There were small amounts of subretinal fluids in the subretinal space (yellow arrow). The LGIR test at 8 weeks (E), showed that there was poor proliferation of the CD4+ T cells in PBMC that were exposed to transplanted iPS-RPE cells. On the other hand, the proliferation of the CD11b+ cells against RPE cells still remained. (F) Color fundus and AF photographs (G) at 8 weeks after surgery in the same patient. (H) OCT shows that the subretinal fluids disappeared after local steroid treatment. (I) Panels show fluorescence angiography images before and at 4 weeks after transplantation, (arrow, grafted RPE cells). There were no leakages from the grafted cells observed in the fluorescence angiography. (J) LGIR FACS results after surgery of the AMD patient (Case 1). There was a decrease in the CD4+/Ki-67+ double-positive cells observed after the sub-Tenon conjunctival injection (STTA; orange arrows), and a decreased in the CD11+/Ki-67+ double-positive cells at 36 weeks after administration of STTA for a total of three times.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 200

Metadata

Authors
Sugita, S., Mandai, M., Hirami, Y., Takagi, S., Maeda, T., Fujihara, M., Matsuzaki, M., Yamamoto, M., Iseki, K., Hayashi, N., Hono, A., Fujino, S., Koide, N., Sakai, N., Shibata, Y., Terada, M., Nishida, M., Dohi, H., Nomura, M., Amano, N., Sakaguchi, H., Hara, C., Maruyama, K., Daimon, T., Igeta, M., Oda, T., Shirono, U., Tozaki, M., Totani, K., Sugiyama, S., Nishida, K., Kurimoto, Y., & Takahashi, M.
Affiliations
  • RIKEN Center for Biosystems Dynamics Research (JP)
  • Kobe City Medical Center General Hospital (JP)
  • Toho University (JP)
  • Kyoto University (JP)
  • The University of Osaka (JP)
  • Hyogo Medical University (JP)
  • Tomey Corporation (Japan) (JP)
Corresponding author
Takahashi, Masayo
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2020-07-13
Volume
9
Issue
7
Pages
2217
ISSN
2077-0383 (ISSN-L)
OpenAlex
W3041366976
Cited by
190
References
33
Citations by year
2026: 27 · 2025: 28 · 2024: 34 · 2023: 24 · 2022: 36 · 2021: 36 · 2020: 5
FWCI
8.18
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • AMED (JP18bm0204002, JP17bk0104002)
  • KAKENHI (25293357, 18H02959, 16K21633)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
Keywords
induced pluripotent stem cells, retinal pigment epithelium, cell transplantation, age-related macular degeneration, HLA matching, immune rejection, local steroid therapy, graft survival, transplant safety, epiretinal membrane, endophthalmitis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.